Health Canada

Formerra and AFC Ecoplastics Forge New Path in Compostable Materials

Retrieved on: 
Thursday, May 2, 2024

ROMEOVILLE, IL, May 2, 2024 - (ACN Newswire) - Formerra, a leader in performance materials distribution, announces a partnership with AFC Ecoplastics to distribute its compostable products across the U.S., Canada, and Mexico.

Key Points: 
  • ROMEOVILLE, IL, May 2, 2024 - (ACN Newswire) - Formerra, a leader in performance materials distribution, announces a partnership with AFC Ecoplastics to distribute its compostable products across the U.S., Canada, and Mexico.
  • Formerra will distribute a range of AFC's compostable resins, compounds, and colorants, including PBAT (polybutylene co-adipate co-terephthalate) and PBS (polybutylene succinate) resins.
  • "AFC has always been at the forefront of sustainable material innovation," said Ha Le, CEO of AFC Ecoplastics.
  • Formerra and AFC Ecoplastics are poised to lead the market in providing viable, sustainable solutions that address regulatory and societal needs.

Government of Canada: Updated 2024 wildfire season projections and preparedness measures

Retrieved on: 
Thursday, May 9, 2024

Environment and Climate Change Canada's (ECCC) meteorologists continue to predict weather conditions for spring and summer 2024 that could lead to greater wildfire risks.

Key Points: 
  • Environment and Climate Change Canada's (ECCC) meteorologists continue to predict weather conditions for spring and summer 2024 that could lead to greater wildfire risks.
  • To counter the growing threat of wildfires in Canada, the federal government will continue to support provinces and territories in wildfire mitigation, response, and monitoring.
  • We are making sure we have the capacity to support provinces and territories and mobilize resources when they are needed for the 2024 wildfire season.
  • With the 2024 wildfire season approaching, our government is ensuring that people in Canada have the tools and information they need to understand and manage the health risks associated with wildfires."

Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

Retrieved on: 
Thursday, May 9, 2024

Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV.

Key Points: 
  • Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV.
  • With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country.
  • "Partnering with IPR-TLV and shipping MDMA to Israel marks a significant advancement for Optimi," said Bill Ciprick, CEO of Optimi Health.
  • Optimi Health Chief Financial Officer, Jacob Safarik, commented, "Obtaining an Export Permit to ship controlled substances globally involves a meticulous process that demands collaboration from various stakeholders.

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.
  • This decision was informed by topline PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community.
  • Amylyx anticipates reporting topline data from all 12 participants at Week 24 in the fall of 2024.
  • Amylyx’ management team will host a conference call and webcast today, May 9, 2024, at 8:00 a.m.

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 8, 2024

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024.
  • Management will host a conference call Thursday, May 9, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2024 financial results.
  • The majority of the U.S. sites are expected to be activated by the end of the third quarter of 2024.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and first quarter 2024 financial results on Thursday, May 9, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Retrieved on: 
Tuesday, May 7, 2024

SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.

Key Points: 
  • SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.
  • SENVELGO™ is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus.
  • Pet owners can give the once-daily liquid oral solution with a small amount of food or directly into the cat's mouth.
  • Dr. Walt Ingwersen, Technical Services Veterinarian with Boehringer Ingelheim Canada, said SENVELGO™ revolutionizes the treatment and management of feline diabetes in newly diagnosed cats.

Government of Canada Supports Lakehead University's project to assist underserved populations in receiving palliative care services

Retrieved on: 
Monday, May 6, 2024

In addition, the project intends to improve the experience of those receiving palliative care by developing meaningful resources for individuals, caregivers, and providers that are tailored to multiple underserved populations.

Key Points: 
  • In addition, the project intends to improve the experience of those receiving palliative care by developing meaningful resources for individuals, caregivers, and providers that are tailored to multiple underserved populations.
  • The Government of Canada's Action Plan on Palliative Care continues to lay a better foundation for coordinated action on palliative and supportive care needs.
  • This project is aligned with the Action Plan priorities which include improving access to palliative care for underserved populations; supporting health system quality by developing palliative care skills and supports for health care providers, families, caregivers, and communities; and enhancing data collection and research.
  • Budget 2017 committed funding of $11 billion over 10 years to provinces and territories for home and community care, including palliative care.

30,000 CANADIANS SAY 'NO' TO BANNING FLAVOURED VAPOUR PRODUCTS

Retrieved on: 
Monday, May 6, 2024

However, Canadians who vape and their allies have made it clear that this is unacceptable.

Key Points: 
  • However, Canadians who vape and their allies have made it clear that this is unacceptable.
  • Many of those who vape will find a way, as the alternative is likely the resumption of inhaling toxic cigarette smoke.
  • "Close to 30,000 Canadians have sent a letter to Ministers Holland and Saks to tell them that flavours matter," said Ms. Papaioannoy.
  • Today, anyone, including minors can buy flavoured vapour products on the black market.

Clean water solutions take centre stage as the 2024 Ingenium Innovation Challenge winner is awarded

Retrieved on: 
Monday, May 6, 2024

OTTAWA, ON, May 6, 2024 /CNW/ - This weekend, Ingenium tapped into the creativity of young Canadians to help encourage action about sustainable management of water and sanitation services.

Key Points: 
  • OTTAWA, ON, May 6, 2024 /CNW/ - This weekend, Ingenium tapped into the creativity of young Canadians to help encourage action about sustainable management of water and sanitation services.
  • The second annual Ingenium Innovation Challenge culminated Sunday night at a livestreamed award ceremony recognizing the brightest ideas that address the complex issue of clean water and sanitation.
  • "I share my deepfelt congratulations to all the participants and to the winning team of our annual Ingenium Innovation Challenge.
  • We hope that the ideas sparked by these bright young adults translate to meaningful action and awareness around the impacts of access to clean water and sanitation.

Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer

Retrieved on: 
Monday, May 6, 2024

MONTREAL, May 6, 2024 /PRNewswire/ -- Congruence Therapeutics, a leading computationally-driven biotechnology company developing a pipeline of novel small molecules for diseases with significant unmet medical need, announced today the appointment of Michael D. Harvey, Ph.D. as Chief Development Officer.

Key Points: 
  • MONTREAL, May 6, 2024 /PRNewswire/ -- Congruence Therapeutics, a leading computationally-driven biotechnology company developing a pipeline of novel small molecules for diseases with significant unmet medical need, announced today the appointment of Michael D. Harvey, Ph.D. as Chief Development Officer.
  • Dr. Harvey also has strong abilities in strategic planning, execution, and alliance management, including pharma partner collaborations.
  • "I am delighted to welcome Michael as the new Chief Development Officer of Congruence.
  • Michael has the strong expertise we were seeking to lead the strategic development of our novel development candidates to Phase 2 proof of concept," stated Dr. Clarissa Desjardins, CEO of Congruence.